{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:21Z","timestamp":1793191041317,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65896-5","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T10:52:15Z","timestamp":1764931935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines"],"prefix":"10.1038","volume":"16","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin R.","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-6928","authenticated-orcid":false,"given":"Ian W.","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3967-7776","authenticated-orcid":false,"given":"Lyndsey T.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minah","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-8621","authenticated-orcid":false,"given":"Jeanne S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8442-637X","authenticated-orcid":false,"given":"Parag","family":"Sahasrabudhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1687-5237","authenticated-orcid":false,"given":"Kimberly F.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2157-2123","authenticated-orcid":false,"given":"Graham M.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristianne P.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddartha","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"McKeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla I.","family":"Cadima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-2273","authenticated-orcid":false,"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Munoz Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mendoza Daroca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0363-1564","authenticated-orcid":false,"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-1718","authenticated-orcid":false,"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1357-9747","authenticated-orcid":false,"given":"Huixian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8414","authenticated-orcid":false,"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-5572","authenticated-orcid":false,"given":"Kayvon","family":"Modjarrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"65896_CR1","unstructured":"HHS. COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries (RAW), https:\/\/healthdata.gov\/Hospital\/COVID-19-Reported-Patient-Impact-and-Hospital-Capa\/g62h-syeh\/about_data (2024)."},{"key":"65896_CR2","unstructured":"CDC. Disease Burden of Flu, https:\/\/www.cdc.gov\/flu\/about\/burden\/ (2023)."},{"key":"65896_CR3","unstructured":"CDC. Preliminary Estimated Flu Disease Burden 2023\u20132024 Flu Season, https:\/\/www.cdc.gov\/flu-burden\/php\/data-vis\/2023-2024.html (2024)."},{"key":"65896_CR4","unstructured":"CDC. COVID Data Tracker, https:\/\/covid.cdc.gov\/covid-data-tracker\/#datatracker-home (2005)."},{"key":"65896_CR5","unstructured":"corneliusroemer. cov-lineages\/pango-designation, https:\/\/github.com\/cov-lineages\/pango-designation\/blob\/master\/lineage_notes.txt (2024)."},{"key":"65896_CR6","unstructured":"FDA. Vaccines and Related Biological Products Advisory Committee June 5, 2024 Meeting Announcement, https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/vaccines-and-related-biological-products-advisory-committee-june-5-2024-meeting-announcement (2024)."},{"key":"65896_CR7","unstructured":"FDA. Vaccines and Related Biological Products Advisory Committee June 15, 2023 Meeting Announcement, https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/vaccines-and-related-biological-products-advisory-committee-june-15-2023-meeting-announcement (2023)."},{"key":"65896_CR8","unstructured":"FDA. Vaccines and Related Biological Products Advisory Committee June 28, 2022 Meeting Announcement, https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement (2022)."},{"key":"65896_CR9","unstructured":"W.H.O. Statement on the Antigen Composition of COVID-19 Vaccines, https:\/\/www.who.int\/news\/item\/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines (2024)."},{"key":"65896_CR10","unstructured":"EMA. ETF Recommends Updating COVID-19 Vaccines to Target New JN.1 Variant, https:\/\/www.ema.europa.eu\/en\/news\/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant (2024)."},{"key":"65896_CR11","unstructured":"FDA. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024, https:\/\/www.fda.gov\/vaccines-blood-biologics\/updated-covid-19-vaccines-use-united-states-beginning-fall-2024 (2024)."},{"key":"65896_CR12","unstructured":"W.H.O. Initial Risk Evaluation of JN.1, 19 December 2023, https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/18122023_jn.1_ire_clean.pdf (2023)."},{"key":"65896_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2402880","volume":"13","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerg. Microbes Infect. 13, 2402880 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"65896_CR14","unstructured":"W.H.O. COVID-19 Epidemiological Update\u20149 October 2024, https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update-edition-172 (2024)."},{"key":"65896_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/vaccines12070734","volume":"12","author":"J Gayed","year":"2024","unstructured":"Gayed, J. et al. Immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine against XBB.1.5, BA.2.86, and JN.1 sublineages: a phase 2\/3 trial. Vaccines 12, 734 (2024).","journal-title":"Vaccines"},{"key":"65896_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/vaccines12020118","volume":"12","author":"J Gayed","year":"2024","unstructured":"Gayed, J. et al. Safety and immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals >\/=12 years old: a phase 2\/3 trial. Vaccines 12, 118 (2024).","journal-title":"Vaccines"},{"key":"65896_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","volume":"32","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315\u2013321 e313 (2024).","journal-title":"Cell Host Microbe"},{"key":"65896_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101701","volume":"5","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster. Cell Rep. Med. 5, 101701 (2024).","journal-title":"Cell Rep. Med."},{"key":"65896_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae370","volume":"11","author":"SY Tartof","year":"2024","unstructured":"Tartof, S. Y. et al. Effectiveness of BNT162b2 XBB vaccine against XBB and JN.1 sublineages. Open Forum Infect. Dis. 11, ofae370 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"65896_CR20","doi-asserted-by":"publisher","unstructured":"Ma, K. C. et al. Effectiveness of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineage hospitalization and a comparison of clinical severity-IVY network, 26 hospitals, October 18, 2023-March 9, 2024. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciae405 (2024).","DOI":"10.1093\/cid\/ciae405"},{"key":"65896_CR21","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1016\/S1473-3099(24)00298-6","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect. Dis. 24, e416 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65896_CR22","unstructured":"MHRA. MHRA Approves Comirnaty JN.1 COVID-19 Vaccine for Adults and Children From Infancy, https:\/\/www.gov.uk\/government\/news\/mhra-approves-comirnaty-jn1-covid-19-vaccine-for-adults-and-children-from-infancy (2024)."},{"key":"65896_CR23","unstructured":"COVID-19 Vaccines and Treatments Portal, https:\/\/covid-vaccine.canada.ca\/ (2024)."},{"key":"65896_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114520","volume":"43","author":"P Li","year":"2024","unstructured":"Li, P. et al. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. Cell Rep. 43, 114520 (2024).","journal-title":"Cell Rep."},{"key":"65896_CR25","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S1473-3099(24)00505-X","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant. Lancet Infect. Dis. 24, e609 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65896_CR26","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. Lancet Infect. Dis. 24, e482\u2013e483 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65896_CR27","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S1473-3099(24)00731-X","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 XEC variant. Lancet Infect. Dis. 24, e736 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65896_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"65896_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01013-9","volume":"9","author":"K Modjarrad","year":"2024","unstructured":"Modjarrad, K. et al. Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine. NPJ Vaccines 9, 229 (2024).","journal-title":"NPJ Vaccines"},{"key":"65896_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33088-0","volume":"13","author":"A Shajahan","year":"2023","unstructured":"Shajahan, A., Pepi, L. E., Kumar, B., Murray, N. B. & Azadi, P. Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern. Sci. Rep. 13, 10053 (2023).","journal-title":"Sci. Rep."},{"key":"65896_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"65896_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae206","volume":"11","author":"P Liu","year":"2024","unstructured":"Liu, P. et al. Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through structural plasticity. Natl Sci. Rev. 11, nwae206 (2024).","journal-title":"Natl Sci. Rev."},{"key":"65896_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.str.2024.06.012","volume":"32","author":"L Li","year":"2024","unstructured":"Li, L. et al. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants. Structure 32, 1055\u20131067 e1056 (2024).","journal-title":"Structure"},{"key":"65896_CR34","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1016\/j.cell.2021.07.025","volume":"184","author":"P Tong","year":"2021","unstructured":"Tong, P. et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell 184, 4969\u20134980.e4915 (2021).","journal-title":"Cell"},{"key":"65896_CR35","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/microorganisms11030580","volume":"11","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. SARS-CoV-2 versus Influenza A Virus: characteristics and co-treatments. Microorganisms 11, 580 (2023).","journal-title":"Microorganisms"},{"key":"65896_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19749-3","volume":"24","author":"Z Gong","year":"2024","unstructured":"Gong, Z. et al. Natural and socio-environmental factors in the transmission of COVID-19: a comprehensive analysis of epidemiology and mechanisms. BMC Public Health 24, 2196 (2024).","journal-title":"BMC Public Health"},{"key":"65896_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14286","volume":"54","author":"M Barosa","year":"2024","unstructured":"Barosa, M., Ioannidis, J. P. A. & Prasad, V. Evidence base for yearly respiratory virus vaccines: current status and proposed improved strategies. Eur. J. Clin. Investig. 54, e14286 (2024).","journal-title":"Eur. J. Clin. Investig."},{"key":"65896_CR38","unstructured":"FDA. Pfizer-BioNTech COVID-19 Vaccine: Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) Authorized For Individuals 6 Months through 11 Years of Age, https:\/\/www.fda.gov\/vaccines-blood-biologics\/coronavirus-covid-19-cber-regulated-biologics\/pfizer-biontech-covid-19-vaccine (2024)."},{"key":"65896_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45274-3","volume":"15","author":"T Tamura","year":"2024","unstructured":"Tamura, T. et al. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. Nat. Commun. 15, 1176 (2024).","journal-title":"Nat. Commun."},{"key":"65896_CR40","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1093\/infdis\/jiae067","volume":"230","author":"S Chalkias","year":"2024","unstructured":"Chalkias, S. et al. Interim report of the reactogenicity and immunogenicity of severe acute respiratory syndrome coronavirus 2 XBB-containing vaccines.  J. Infect. Dis. 230, e279\u2013e286 (2024).","journal-title":"J. Infect. Dis."},{"key":"65896_CR41","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"65896_CR42","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"65896_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/science.abi9745","volume":"373","author":"Y Cai","year":"2021","unstructured":"Cai, Y. et al. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science 373, 642\u2013648 (2021).","journal-title":"Science"},{"key":"65896_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1126\/science.abl9463","volume":"374","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science 374, 1353\u20131360 (2021).","journal-title":"Science"},{"key":"65896_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.abf2303","volume":"372","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science 372, 525\u2013530 (2021).","journal-title":"Science"},{"key":"65896_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110729","volume":"39","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Rep. 39, 110729 (2022).","journal-title":"Cell Rep."},{"key":"65896_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"65896_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jinf.2023.10.008","volume":"87","author":"C Fenwick","year":"2023","unstructured":"Fenwick, C. et al. Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys. J. Infect. 87, 524\u2013537 (2023).","journal-title":"J. Infect."},{"key":"65896_CR49","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.cell.2022.03.018","volume":"185","author":"LB Rodda","year":"2022","unstructured":"Rodda, L. B. et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell 185, 1588\u20131601 e1514 (2022).","journal-title":"Cell"},{"key":"65896_CR50","doi-asserted-by":"publisher","unstructured":"Li, P. et al. Neutralization and stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 subvariants. bioRxiv. https:\/\/doi.org\/10.1101\/2024.09.04.611219 (2024).","DOI":"10.1101\/2024.09.04.611219"},{"key":"65896_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105185","volume":"105","author":"S Slamanig","year":"2024","unstructured":"Slamanig, S. et al. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. EBioMedicine 105, 105185 (2024).","journal-title":"EBioMedicine"},{"key":"65896_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49443-2","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective. Nat. Commun. 15, 5589 (2024).","journal-title":"Nat. Commun."},{"key":"65896_CR53","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/v16040559","volume":"16","author":"ZH Yang","year":"2024","unstructured":"Yang, Z. H. et al. Measles virus-based vaccine expressing membrane-anchored spike of SARS-CoV-2 inducing efficacious systemic and mucosal humoral immunity in hamsters. Viruses 16, 559 (2024).","journal-title":"Viruses"},{"key":"65896_CR54","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.cell.2023.04.024","volume":"186","author":"MAG Hoffmann","year":"2023","unstructured":"Hoffmann, M. A. G. et al. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell 186, 2380\u20132391 e2389 (2023).","journal-title":"Cell"},{"key":"65896_CR55","doi-asserted-by":"publisher","unstructured":"Singh, O. N. et al. Immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines for SARS-CoV-2. bioRxiv, 2024.2008.2023.609366. https:\/\/doi.org\/10.1101\/2024.08.23.609366 (2024).","DOI":"10.1101\/2024.08.23.609366"},{"key":"65896_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114567","volume":"43","author":"A Muik","year":"2024","unstructured":"Muik, A. et al. Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1. Cell Rep. 43, 114567 (2024).","journal-title":"Cell Rep."},{"key":"65896_CR57","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"CY Liang","year":"2024","unstructured":"Liang, C. Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960 (2024).","journal-title":"Nature"},{"key":"65896_CR58","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2024.02.017","volume":"57","author":"TS Johnston","year":"2024","unstructured":"Johnston, T. S. et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity 57, 912\u2013925 e914 (2024).","journal-title":"Immunity"},{"key":"65896_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature17655","volume":"532","author":"LK Beura","year":"2016","unstructured":"Beura, L. K. et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532, 512\u2013516 (2016).","journal-title":"Nature"},{"key":"65896_CR60","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1056\/NEJMc2103916","volume":"384","author":"N Doria-Rose","year":"2021","unstructured":"Doria-Rose, N. et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N. Engl. J. Med. 384, 2259\u20132261 (2021).","journal-title":"N. Engl. J. Med."},{"key":"65896_CR61","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","volume":"185","author":"M Gagne","year":"2022","unstructured":"Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185, 1556\u20131571 e1518 (2022).","journal-title":"Cell"},{"key":"65896_CR62","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1126\/science.adc9127","volume":"378","author":"YJ Park","year":"2022","unstructured":"Park, Y. J. et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 378, 619\u2013627 (2022).","journal-title":"Science"},{"key":"65896_CR63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","volume":"29","author":"SM Scheaffer","year":"2023","unstructured":"Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med 29, 247\u2013257 (2023).","journal-title":"Nat. Med"},{"key":"65896_CR64","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","volume":"33","author":"F Sallusto","year":"2010","unstructured":"Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. Immunity 33, 451\u2013463 (2010).","journal-title":"Immunity"},{"key":"65896_CR65","unstructured":"Havers, F. P. COVID-19\u2013Associated Hospitalizations among Children and Adults\u2014COVID-NET, https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/02-COVID-Havers-508.pdf (2024)."},{"key":"65896_CR66","unstructured":"CDC. About Provisional Mortality Statistics, 2018 through Last Week, https:\/\/wonder.cdc.gov\/mcd-icd10-provisional.html."},{"key":"65896_CR67","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/infdis\/jiad353","volume":"228","author":"N Lasrado","year":"2023","unstructured":"Lasrado, N. & Barouch, D. H. SARS-CoV-2 hybrid immunity: the best of both worlds.  J. Infect. Dis. 228, 1311\u20131313 (2023).","journal-title":"J. Infect. Dis."},{"key":"65896_CR68","doi-asserted-by":"publisher","first-page":"e1010161","DOI":"10.1371\/journal.ppat.1010161","volume":"18","author":"C Munoz-Fontela","year":"2022","unstructured":"Munoz-Fontela, C. et al. Advances and gaps in SARS-CoV-2 infection models. PLoS Pathog. 18, e1010161 (2022).","journal-title":"PLoS Pathog."},{"key":"65896_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46025-y","volume":"13","author":"N Patel","year":"2023","unstructured":"Patel, N. et al. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. Sci. Rep. 13, 19176 (2023).","journal-title":"Sci. Rep."},{"key":"65896_CR70","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S1473-3099(23)00779-X","volume":"24","author":"U Marking","year":"2024","unstructured":"Marking, U. et al. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden. Lancet Infect. Dis. 24, e80\u2013e81 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65896_CR71","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S1473-3099(23)00690-4","volume":"24","author":"MV Stankov","year":"2024","unstructured":"Stankov, M. V. et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect. Dis. 24, e1\u2013e3 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65896_CR72","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S1473-3099(23)00784-3","volume":"24","author":"Y Kosugi","year":"2024","unstructured":"Kosugi, Y. et al. Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals. Lancet Infect. Dis. 24, e147\u2013e148 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65896_CR73","doi-asserted-by":"publisher","unstructured":"Figueroa, A. L. et al. Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 subvariants in adult participants. medRxiv, 2025.2005.2002.25325954. https:\/\/doi.org\/10.1101\/2025.05.02.25325954 (2025).","DOI":"10.1101\/2025.05.02.25325954"},{"key":"65896_CR74","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"65896_CR75","unstructured":"PyMOL Molecular Graphics System by Schr\u00f6dinger v. 3.0, https:\/\/www.pymol.org\/ (2025)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65896-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65896-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65896-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:06:59Z","timestamp":1764936419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65896-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65896"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65896-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare a competing interest. All authors are current or former employees of Pfizer or BioNTech and may, therefore, be respective shareholders and\/or hold stock options. Pfizer and BioNTech participated in the design, analysis and interpretation of the data as well as the writing of this report and the decision to publish. W.L., A.M., U.S., K.A.S., and K.M. are inventors on patents and patent applications related to the COVID-19 vaccine. A.M. and U.S. are inventors on patents and patent applications related to RNA technology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10914"}}